文献速递血栓与止血

尾静脉横断出血模型评估重组凝血因子VIIIa和VIIa在A型血友病大鼠体内的作用

In vivo effect of rFVIII and rFVIIa in hemophilia A rats evaluated by the Tail Vein Transection Bleeding Model.
PubMed 文献 · J Thromb Haemost · 2022-12-22

本研究在A型血友病(HA)大鼠中实施尾静脉横断(TVT)出血模型,并用重组凝血因子VIIa(rFVIIa)和VIII(rFVIII)进行剂量反应研究。rFVIII的ED50估计为1.75 U/kg,rFVIIa为0.37 mg/kg,完全纠正分别见于15 U/kg和2.7 mg/kg。凝血酶生成试验(TGT)和旋转血栓弹力测定(ROTEM)结果与体内药效学强相关。

要点

  • HA大鼠TVT出血模型可用于评估止血药物的体内药效学。
  • rFVIII的ED50为1.75 U/kg,rFVIIa的ED50为0.37 mg/kg。
  • TGT和ROTEM结果与体内药效学强相关。

核心结论

  • HA大鼠TVT出血模型是评估止血化合物体内药效学的有用工具,且与TGT和ROTEM结果强相关,为HA大鼠模型在临床前研究中增加价值。

研究设计与样本

  • 在HA大鼠中实施TVT出血模型,并用rFVIIa和rFVIII进行剂量反应研究,之后采集全血和血浆进行TGT和ROTEM评估。

主要发现

  • rFVIII的药理学窗口为≤15 U/kg,rFVIIa为≤2.7 mg/kg。
  • rFVIII的ED50估计为1.75 U/kg,rFVIIa为0.37 mg/kg。
  • 完全纠正分别见于rFVIII 15 U/kg和rFVIIa 2.7 mg/kg。
  • TGT和ROTEM中rFVIII和rFVIIa的反应与体内药效学强相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical bleeding models increase current hemophilia A (HA) knowledge and aid the development of new pharmacological treatments. There are several well-established mouse bleeding models, but limited options are available for rat models despite their high resemblance to human disease process. OBJECTIVE: To provide a comprehensive description of the tail vein transection (TVT) bleeding model in HA rats and examine the correlation between in vivo pharmacological efficacy and global hemostatic assays. METHODS: The TVT bleeding model was implemented in HA rats and used to perform dose-response studies with recombinant coagulation factors VIIa (rFVIIa) and VIII (rFVIII). After the TVT bleeding model, whole blood and plasma were collected from rats and evaluated with thrombin generation test (TGT) and rotational thromboelastometry (ROTEM). RESULTS: Using the TVT bleeding model, the potency of rFVIII and rFVIIa treatments in HA rats were assessed, and the pharmacological windows established for rFVIII (≤15 U/kg) and rFVIIa (≤2.7 mg/kg). ED50 was estimated to be 1.75 U/kg for rFVIII and 0.37 mg/kg for rFVIIa, whereas complete normalization was observed with 15 U/kg and 2.7 mg/kg respectively. Furthermore, responses to rFVIII and rFVIIa in the TGT and ROTEM assays strongly correlated to in vivo pharmacological efficacy. CONCLUSION: The TVT bleeding model in HA rats is a useful tool to assess the pharmacodynamic effects of hemostatic compounds in vivo, and strongly correlates to results obtained with TGT and ROTEM in HA rats, adding further value to the HA rat model in preclinical research.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Stagaard R, Øvlisen GO, Klæbel JH, et al. In vivo effect of rFVIII and rFVIIa in hemophilia A rats evaluated by the Tail Vein Transection Bleeding Model. J Thromb Haemost. 2022. PMID: 36696187. doi:10.1016/j.jtha.2022.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。